2023 World Conference on Lung Cancer (Posters)-EP13.03. Efficacy of First-Line Tislelizumab Plus Etoposide and Carboplatin in ES-SCLC

Pdf Summary

This study evaluates the efficacy and safety of tislelizumab, a monoclonal antibody targeting PD-1, in combination with etoposide and carboplatin as a first-line treatment for extensive-stage small cell lung cancer (ES-SCLC). ES-SCLC is an aggressive malignancy that metastasizes early. The standard first-line treatment involves cisplatin-based doublet chemotherapy with immunotherapy. However, tislelizumab has not been approved for ES-SCLC. <br /><br />The study is a prospective, single-arm trial involving eight patients. The primary endpoint is overall survival (OS), and secondary endpoints include progression-free survival (PFS), objective response rate (ORR), and treatment-related adverse events (TRAEs). Patients received four cycles of tislelizumab, etoposide, and carboplatin, followed by tislelizumab maintenance until disease progression or intolerable side effects.<br /><br />The results show a promising efficacy of tislelizumab in combination with etoposide and carboplatin. The overall response rate (ORR) was 62.5%, and the disease control rate (DCR) was 87.5%. Four patients (50.0%) experienced disease progression during the follow-up period. The median progression-free survival (PFS) was 14.3 months, and the median overall survival (OS) was not reached.<br /><br />Based on these findings, the authors conclude that tislelizumab plus etoposide and carboplatin presents a promising first-line treatment option for ES-SCLC. However, patient enrollment is ongoing, and long-term efficacy, such as overall survival, will be evaluated in the future. <br /><br />In summary, this study demonstrates the potential efficacy and acceptable safety profile of tislelizumab plus etoposide and carboplatin as a first-line treatment for extensive-stage small cell lung cancer. However, further research and evaluation of long-term outcomes are needed.

Asset Subtitle

Chu Qian

Meta Tag

Speaker Chu Qian

Topic SCLC & Neuroendocrine Tumors: First Line Therapy

Keywords

tislelizumab

monoclonal antibody

PD-1

etoposide

carboplatin

extensive-stage small cell lung cancer

ES-SCLC

overall survival

progression-free survival

objective response rate